Biodesix (NASDAQ:BDSX) Issues Earnings Results, Misses Estimates By $0.01 EPS

Key Points

• Biodesix reported a quarterly EPS of ($0.08), missing analysts' estimates by $0.01, with revenues of $20.02 million exceeding expectations of $18.47 million.
• The company's stock traded down by $0.05 to $0.40 following the earnings report, with a market capitalization of $58.70 million and significant negative margins.
• Analysts have adjusted their price targets for Biodesix, with a consensus target price of $1.75 and a consensus rating of "Moderate Buy" based on recent reports.

Biodesix (NASDAQ:BDSX - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.01), Zacks reports. Biodesix had a negative return on equity of 206.10% and a negative net margin of 53.66%. The business had revenue of $20.02 million during the quarter, compared to the consensus estimate of $18.47 million. Biodesix updated its FY 2025 guidance to EPS.

Biodesix Stock Performance

Shares of NASDAQ:BDSX traded down $0.05 during midday trading on Friday, hitting $0.40. The company's stock had a trading volume of 1,125,370 shares, compared to its average volume of 1,437,121. The stock has a market capitalization of $58.70 million, a price-to-earnings ratio of -1.38 and a beta of 0.99. The stock's 50 day simple moving average is $0.32 and its 200 day simple moving average is $0.56. Biodesix has a fifty-two week low of $0.17 and a fifty-two week high of $2.04. The company has a debt-to-equity ratio of 3.32, a quick ratio of 2.22 and a current ratio of 2.22.

Analyst Ratings Changes

A number of equities analysts have issued reports on BDSX shares. Craig Hallum decreased their price target on Biodesix from $3.00 to $1.50 and set a "buy" rating for the company in a research note on Wednesday, May 14th. William Blair reiterated a "market perform" rating on shares of Biodesix in a research report on Wednesday, May 14th. Lake Street Capital reduced their target price on Biodesix from $3.00 to $2.00 and set a "buy" rating for the company in a report on Wednesday, May 14th. Scotiabank reduced their price objective on Biodesix from $3.00 to $2.00 and set a "sector outperform" rating for the company in a research note on Wednesday, May 21st. Finally, Canaccord Genuity Group dropped their target price on Biodesix from $2.50 to $1.50 and set a "buy" rating on the stock in a report on Wednesday, May 14th. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, Biodesix presently has a consensus rating of "Moderate Buy" and a consensus target price of $1.75.

About Biodesix

Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.